Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • 9th International Congress on Obesity - Abstracts and Short Reports
  • Published:

9th International Congress On Obesity - Abstracts and Short Reports

Race affects insulin and GLP-1 secretion and response to a long-acting somatostatin analogue in obese adults

International Journal of Obesity volume 28, pages 330–333 (2004)Cite this article

Abstract

OBJECTIVE: This study investigated (1) the effect of octreotide-LAR (Sandostatin-LAR®Depot; Novartis) on the enteroinsular axis in a biracial cohort of severely obese adults, (2) whether octreotide suppression of insulin secretion occurs by both a direct β-cell effect and through mediating a glucagon-like peptide 1 (GLP-1) response, and (3) whether differences in GLP-1 concentrations could explain racial differences in insulin concentrations.

DESIGN: Prospective, open-label trial using a pre–post test design.

SETTING: Single university, clinical research center.

SUBJECTS: In all, 42 healthy, severely obese Caucasian and African-American (AA) adults (93% female, 64% Caucasian, age=37.8±1.2 y, weight=123±4.2 kg, BMI=44.5±1 kg/m2), recruited through physician referral and newspaper ads, participated in the study.

INTERVENTIONS: Indices of β-cell activity, insulin and GLP-1 response before and during a 75-gm oral glucose tolerance test were determined before and after 24 weeks of octreotide-LAR.

RESULTS: AA exhibited higher β-cell activity, and insulin and GLP-1 concentrations than Caucasians. Octreotide-LAR suppressed the insulin and GLP-1 levels in both groups.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Kieffer TJ, Habener JF . The glucagon-like peptides. Endocr Rev 1999; 20: 876–913.

    Article  CAS  Google Scholar 

  2. Bertoli A, Magnaterra R, Borboni P, Marini MA, Barini A, Fusco A, Bollea MR . Dose-dependent effect of octreotide on insulin secretion after OGTT in obesity. Horm Res 1998; 49: 17–21.

    CAS  PubMed  Google Scholar 

  3. Giustina A, Girelli A, Buffoli MG, Cimino A, Legati F, Valentini U, Giustina G . Low-dose octreotide is able to cause a maximal inhibition of the glycemic responses to a mixed meal in obese type 2 diabetic patients treated with insulin. Diabetes Res Clin Pract 1991; 14: 47–54.

    Article  CAS  Google Scholar 

  4. Lunetta M, Di Mauro M, Le Moli R, Burrafato S . Long-term octreotide treatment reduced hyperinsulinemia, excess body weight and skin lesions in severe obesity with Acanthosis nigricans. J Endocrinol Invest 1996; 19: 699–703.

    Article  CAS  Google Scholar 

  5. Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen DM, Xiong Y, Hayes EC, Parmar RM, Foor F, Mitra SW, Degrado SJ, Shu M, Klopp JM, Cai SJ, Blake A, Chan WW, Pasternak A, Yang L, Patchett AA, Smith RG, Chapman KT, Schaeffer JM . Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998; 282: 737–740.

    Article  CAS  Google Scholar 

  6. Sluiter WJ, Erkelens DW, Terpstra P, Reitsma WD, Doorenbos H . Glucose tolerance and insulin release, a mathematical approach. II. Approximation of the peripheral insulin resistance after oral glucose loading. Diabetes 1976; 25: 245–249.

    Article  CAS  Google Scholar 

  7. Matsuda M, DeFronzo RA . Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462–1470.

    Article  CAS  Google Scholar 

  8. Toft I, Bonaa KH, Lindal S, Jenssen T . Insulin kinetics, insulin action, and muscle morphology in lean or slightly overweight persons with impaired glucose tolerance. Metabolism 1998; 47: 848–854.

    Article  CAS  Google Scholar 

  9. Oben J, Morgan L, Fletcher J, Marks V . Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7–36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol 1991; 130: 267–272.

    Article  CAS  Google Scholar 

  10. Delgado E, Luque MA, Alcantara A, Trapote MA, Clemente F, Galera C, Valverde I, Villanueva-Penacarrillo ML . Glucagon-like peptide-1 binding to rat skeletal muscle. Peptides 1995; 16: 225–229.

    Article  CAS  Google Scholar 

  11. Dupre J, Greenidge N, McDonald TJ, Ross SA, Rubinstein D . Inhibition of actions of glucagon in adipocytes by gastric inhibitory polypeptide. Metabolism 1976; 25: 1197–1199.

    Article  CAS  Google Scholar 

  12. Ebert R, Frerichs H, Creutzfeldt W . Impaired feedback control of fat induced gastric inhibitory polypeptide (GIP) secretion by insulin in obesity and glucose intolerance. Eur J Clin Invest 1979; 9: 129–135.

    Article  CAS  Google Scholar 

  13. Yip RG, Wolfe MM . GIP biology and fat metabolism. Life Sci 2000; 66: 91–103.

    Article  CAS  Google Scholar 

  14. Verdich C, Toubro S, Buemann B, Lysgard Madsen J, Juul Holst J, Astrup A . The role of postprandial releases of insulin and incretin hormones in meal-induced satiety—effect of obesity and weight reduction. Int J Obes Relat Metab Disord 2001; 25: 1206–1214.

    Article  CAS  Google Scholar 

  15. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK . Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002; 110: 43–52.

    Article  CAS  Google Scholar 

  16. Barragan JM, Rodriguez RE, Blazquez E . Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7–36) amide in rats. Am J Physiol 1994; 266: E459–66.

    CAS  PubMed  Google Scholar 

  17. Edwards CM, Edwards AV, Bloom SR . Cardiovascular and pancreatic endocrine responses to glucagon-like peptide-1(7–36) amide in the conscious calf. Exp Physiol 1997; 82: 709–716.

    Article  CAS  Google Scholar 

  18. Wei Y, Mojsov S . Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995; 358: 219–224.

    Article  CAS  Google Scholar 

  19. Edwards CM, Todd JF, Ghatei MA, Bloom SR . Subcutaneous glucagon-like peptide-1 (7–36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects. Clin Sci (Lond) 1998; 95: 719–724.

    Article  CAS  Google Scholar 

  20. Wettergren A, Wojdemann M, Holst JJ . The inhibitory effect of glucagon-like peptide-1 (7–36) amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9–36)amide. Peptides 1998; 19: 877–882.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Funding for this study was provided in part by Novartis Pharmaceuticals Corporation and the University of Tennessee Health Science Center General Clinical Resource Center (UTHSC GCRC) [USPH RR000211]. We would also like to thank the nurses in the UTHSC GCRC and the HELP Center for their assistance with the study. This work was supported in part by University of Tennessee GCRC 5M01RR 00211, and by a research grant from Novartis Pharmaceuticals Corporation.

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, USA

    P A Velasquez-Mieyer, M Christensen, K A Spencer & G A Burghen

  2. Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA

    G E Umpierrez

  3. Department of Pediatrics, University of California, San Francisco, 94143, CA, USA

    R H Lustig

  4. Department of Nursing, University of Tennessee Health Science Center, Memphis, TN, USA

    A K Cashion & P A Cowan

Authors
  1. P A Velasquez-Mieyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G E Umpierrez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R H Lustig
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A K Cashion
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P A Cowan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Christensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K A Spencer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G A Burghen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P A Velasquez-Mieyer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Velasquez-Mieyer, P., Umpierrez, G., Lustig, R. et al. Race affects insulin and GLP-1 secretion and response to a long-acting somatostatin analogue in obese adults. Int J Obes 28, 330–333 (2004). https://doi.org/10.1038/sj.ijo.0802561

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0802561

Keywords

This article is cited by

Search

Advanced search

Quick links